ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last461 to 480 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
CSL112 vs Placebo: Number of Participants With First Occurrence of MI312 of 9,112

342 of 9,107

-0.3 points

-0.9 to 0.2

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With Occurrence of All-cause Death341 of 9,112

345 of 9,107

-0.0 points

-0.6 to 0.5

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke)439 of 9,112

472 of 9,107

-0.4 points

-1.0 to 0.3

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With First Occurrence of CV Death, MI, or Stroke622 of 9,112

683 of 9,107

-0.7 points

-1.4 to 0.1

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With First Occurrence of CV Death, MI, or Stroke885 of 9,112

944 of 9,107

-0.7 points

-1.5 to 0.2

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With First Occurrence of Stroke57 of 9,112

49 of 9,107

0.1 points

-0.1 to 0.3

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: deaths from any cause348 of 9,112

355 of 9,107

-0.1 points

-0.6 to 0.5

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With Occurrence of CV Death107 of 9,112

128 of 9,107

-0.2 points

-0.6 to 0.1

18,219NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Apixaban vs Warfarin: Number of Participants With Events of All-Cause Death During the Intended Treatment Period603 of 9,120

669 of 9,081

-0.8 points

-1.5 to -0.0

18,201NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Ezetimide/Simvastatin vs Simvastatin: serious adverse events3,640 of 9,067

3,649 of 9,077

-0.1 points

-1.5 to 1.4

18,144NCT00202878

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Apixaban vs Warfarin: Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period613 of 9,088

877 of 9,052

-2.9 points

-3.7 to -2.1

18,140NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Apixaban vs Warfarin: Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period327 of 9,088

462 of 9,052

-1.5 points

-2.1 to -0.9

18,140NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Apixaban vs Warfarin: Number of Participants With All Bleeding Events During Treatment Period2,356 of 9,088

3,060 of 9,052

-7.9 points

-9.2 to -6.6

18,140NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Apixaban vs Warfarin: Number of Participants With Net-Clinical Benefit During Treatment Period459 of 9,088

608 of 9,052

-1.7 points

-2.4 to -1.0

18,140NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Warfarin vs Apixaban: serious adverse events3,182 of 9,088

3,302 of 9,052

-1.5 points

-2.9 to -0.1

18,140NCT00412984

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

CSL112 vs Placebo: Number of Participants With Treatment-related Adverse Events350 of 9,010

304 of 9,027

0.5 points

-0.0 to 1.1

18,037NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With Serious Adverse Events (SAEs)1,514 of 9,010

1,557 of 9,027

-0.4 points

-1.5 to 0.7

18,037NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: Number of Participants With Adverse Events3,938 of 9,010

3,927 of 9,027

0.2 points

-1.2 to 1.7

18,037NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

CSL112 vs Placebo: serious adverse events1,514 of 9,010

1,557 of 9,027

-0.4 points

-1.5 to 0.7

18,037NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

ROSUVASTATIN 20 MG vs PLACEBO: serious adverse events1,205 of 8,869

1,216 of 8,864

-0.1 points

-1.1 to 0.9

17,733NCT00239681

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=24

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03473223-14903782",
        "title": "CSL112 vs Placebo: Number of Participants With First Occurrence of MI",
        "summary": "312 of 9112 against 342 of 9107; risk difference -0.3 points, 95% interval -0.9 to 0.2; NCT03473223, Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT03473223-14903782",
        "nct_id": "NCT03473223",
        "kind": "outcome",
        "participants": 18219,
        "risk_difference": {
          "value": -0.0033129683550545755,
          "lower": -0.008733697779427178,
          "upper": 0.0020972635497298825
        },
        "group_1": "312 of 9,112",
        "group_2": "342 of 9,107",
        "difference": "-0.3 points",
        "interval": "-0.9 to 0.2",
        "trial_title": "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome"
      },
      {
        "id": "NCT03473223-17308645",
        "title": "CSL112 vs Placebo: Number of Participants With Occurrence of All-cause Death",
        "summary": "341 of 9112 against 345 of 9107; risk difference -0.0 points, 95% interval -0.6 to 0.5; NCT03473223, Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT03473223-17308645",
        "nct_id": "NCT03473223",
        "kind": "outcome",
        "participants": 18219,
        "risk_difference": {
          "value": -0.000459768956970745,
          "lower": -0.0060012881271683345,
          "upper": 0.005080187023452176
        },
        "group_1": "341 of 9,112",
        "group_2": "345 of 9,107",
        "difference": "-0.0 points",
        "interval": "-0.6 to 0.5",
        "trial_title": "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=25",
  "request_id": "zMb-ZWk6PJgwVbwr"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?